首页 工具
登录
购物车
Venetoclax

Venetoclax

热 门
产品编号 T2119   CAS 1257044-40-8
别名: GDC-0199, ABT 199, 维奈妥拉, ABT-199, ABT199

Venetoclax (ABT-199) 是一种 Bcl-2 抑制剂 (Ki<0.01 nM),具有高效性、选择性和口服活性。Venetoclax 与 Bcl-xL 和 Bcl-W 的亲和力降低了 3 个数量级(Kis=48/245 nM)。Venetoclax 可以诱导自噬凋亡

TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
Venetoclax Chemical Structure
Venetoclax, CAS 1257044-40-8
规格 价格/CNY 货期 数量
5 mg ¥ 495 现货
10 mg ¥ 695 现货
50 mg ¥ 895 现货
100 mg ¥ 1,160 现货
500 mg ¥ 2,995 现货
1 g ¥ 4,847 现货
1 mL * 10 mM (in DMSO) ¥ 663 现货
618惊喜特惠 4重福利大放送
药物设计专题培训
千万补贴 助力科研
BCA蛋白浓度测定试剂盒限时半价
产品目录号及名称: Venetoclax (T2119)
点击图片重新获取验证码
选择批次  
纯度: 99.96%
纯度: 99.95%
纯度: 99.92%
纯度: 99.71%
纯度: 99%
纯度: 98.71%
TargetMol batch loading
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Venetoclax (ABT-199) is a Bcl-2 inhibitor (Ki<0.01 nM) with potent, selective, and orally active properties. Venetoclax has a 3-order-of-magnitude lower affinity for Bcl-xL and Bcl-W (Kis=48/245 nM). Venetoclax induces autophagy and apoptosis.
靶点活性 BCL-XL:48 nM (Ki, cell free), BCL2:<0.01 nM (Ki, cell free)
体外活性 方法:11 种人 T 细胞急性淋巴细胞白血病细胞 T-ALL 用 Venetoclax (0-12 μM) 处理 48 h,使用 Celltiter-Glo Luminescent Cell Viability Assay 检测细胞活力。
结果:Venetoclax 对 11 种 T-ALL 的 IC50 值范围为 0.2-10 μM。[1]
方法:人急性淋巴白血病细胞 RS4;11 用 Venetoclax (0.01-5 μM) 孵育 3.5 h,使用 Caspase-GLO kit 评估 Caspase-3/7 活性。
结果: Venetoclax 诱导 Caspase 的激活,这是细胞凋亡特征之一。[2]
方法:人原代 HCL 白血病细胞用 Venetoclax (0.1-1 μM) 处理 24 h,使用 Flow Cytometry 方法检测细胞死亡情况。
结果:Venetoclax 以剂量依赖的方式显著增加了 HCL 细胞的细胞死亡。[3]
体内活性 方法:为检测体内抗肿瘤活性,将 Venetoclax (100 mg/kg in 60% PG+30% PEG 400+10% ethanol) 口服给药给携带人弥漫大B细胞淋巴瘤 Toledo 的 C.B-17 SCID-beige 小鼠,每天一次,持续二十一天。
结果:Venetoclax 可显著抑制 Toledo 肿瘤的生长 (TGImax=93%,TGD=220%)。[2]
方法:为检测体内抗肿瘤活性,将 Venetoclax (50 mg/kg in 10% ethanol+30% PEG 400+60% Phosal 50PG,口服给药,每天一次) 和 anti-PD-1 (10 mg/kg in PBS,腹腔注射,每四天三次) 给药给携带小鼠结直肠癌肿瘤 MC38 的 C57BL/6 小鼠,持续十四天。
结果:Venetoclax 可以增强免疫检查点抑制剂 (ICIs) 的抗肿瘤功效,同时增加 PD-1+T 效应记忆细胞。Venetoclax 在体外对抗原刺激的反应中不会损害人类 T 细胞的功能,也不会拮抗 anti-PD-1 诱导的 T 细胞活化。[4]
激酶实验 The equilibrium binding experiments of fluorescent peptides to Bcl-xL protein were performed in an Analyst 96-well plate reader under the following conditions: each individual well in a 96-well assay plate contained 5 μl DMSO, 15 nM fluorescent peptide, and increasing concentrations (from 0 to 2.24 μM) of Bcl-xL protein in assay buffer in a final volume of 125 μl. The plate was mixed on a shaker for 1 min and incubated at room temperature for an additional 15 min. The polarization in millipolarization units (mP) was measured at room temperature with an excitation wavelength at 485 nm and an emission wavelength at 530 nm. For assay stability testing, a plate containing a binding experiment was measured at different times over a 24-h period. Between each reading, the plate was covered with parafilm to prevent any solution evaporation. To determine the effect of DMSO on the assay, binding experiments were performed under conditions similar to those described above except that the amount of DMSO was varied from 0 to 4 to 8%. All experimental data were analyzed using Prism 3.0 software and Kd values were generated by fitting the experimental data using a sigmoidal dose-response nonlinear regression model [1].
细胞实验 RS4;11 cells were seeded at 50,000 per well in 96-well plates and treated with compounds diluted in half-log steps starting at 1 μM and ending at 0.00005 μM. All other leukemia and lymphoma cell lines were seeded at 15,000–20,000 cells per well in the appropriate medium and incubated with ABT-199 or navitoclax for 48 h. Effects on proliferation were determined using Cell TiterGlo reagent. EC50 values were determined by nonlinear regression analysis of the concentration-response data. Mouse FL5.12–BCL-2 and FL5.12–BCL-XL cells were propagated and assessed as described previously. Bak?/? Bax?/? double knockout mouse embryonic fibroblasts were seeded into 96-well microtiter plates at 5,000 cells per well in DMEM supplemented with 10% FBS. ABT-199 in the same culture medium was added in half-log dilutions starting at 5 μM. The cells were then incubated at 37 °C (5% CO2) for 48 h, and the effects on proliferation were determined using Cell TiterGlo reagent according to the manufacturer's instructions [1].
动物实验 Female C.B-17 SCID mice (DoHH2 and Granta-519 xenografts) and female C.B-17 SCID-beige mice (RS4;11 and Toledo xenografts) were inoculated with 1 × 10^6 (DoHH2) or 5 × 10^6 (Granta-519, Toledo and RS4;11) cells subcutaneously in the right flank. The inoculation volume (0.2 ml) comprised a 50:50 mixture of cells in growth media and Matrigel. Electronic calipers were used to measure the length and width of each tumor 2–3 times per week. Tumor volume was estimated by applying the following equation: volume = length × width2/2. When tumors reached approximately 220 mm3, mice were size matched (day 0) into treatment and control groups. All xenograft trials were conducted using ten mice per group, and all mice were ear tagged and monitored individually throughout the studies. ABT-199 was formulated for oral dosing in 60% phosal 50 propylene glycol (PG), 30% polyethylene glycol (PEG) 400 and 10% ethanol, and bendamustine and rituximab were formulated in accordance with the manufacturer's instructions. ABT-199 was delivered approximately 2 h before bendamustine or bendamustine plus rituximab. TGImax was calculated as the greatest treatment response using the following equation: TGImax = (1 ? mean tumor volume of the treated group/mean tumor volume of the vehicle control group) × 100. The TGD (%) was determined as the percentage increase of the median time period for the treatment group to reach an arbitrary tumor volume of 1,000 mm3 relative to the vehicle control group. A complete tumor regression response was the portion of the population with tumors ≤25 mm3 for at least three consecutive measurements [1].
别名 GDC-0199, ABT 199, 维奈妥拉, ABT-199, ABT199
化合物与蛋白结合的复合物

T2119_2

crystal structure of BCL-2 with venetoclax

分子量 868.44
分子式 C45H50ClN7O7S
CAS No. 1257044-40-8

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

H2O: < 1 mg/mL (insoluble or slightly soluble)

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 100 mg/mL (115.15 mM)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.1515 mL 5.7575 mL 11.5149 mL 28.7873 mL
5 mM 0.2303 mL 1.1515 mL 2.303 mL 5.7575 mL
10 mM 0.1151 mL 0.5757 mL 1.1515 mL 2.8787 mL
20 mM 0.0576 mL 0.2879 mL 0.5757 mL 1.4394 mL
50 mM 0.023 mL 0.1151 mL 0.2303 mL 0.5757 mL
100 mM 0.0115 mL 0.0576 mL 0.1151 mL 0.2879 mL

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Peirs S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014 Dec 11;124(25):3738-47. 2. Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. 3. Vereertbrugghen A, et al. In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia. Front Oncol. 2021 Jul 26;11:598319. 4. Kohlhapp FJ, et al. Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade. Cancer Discov. 2021 Jan;11(1):68-79. 5. Capoci I R G, Faria D R, Sakita K M, et al. Repurposing approach identifies new treatment options for invasive fungal disease[J]. Bioorganic chemistry. 2019 Mar;84:87-97.

TargetMol Library Books文献引用

1. Lima K, Pereira-Martins D A, de Miranda L B L, et al.The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy.Blood cancer journal.2022, 12(11): 1-11. 2. Pan G, Zhong M, Yao J, et al.Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.Journal of Cancer Research and Clinical Oncology.2022: 1-17. 3. Gao P, Zhang W, Fang X, et al.Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS/MS and its application in acute myeloid leukemia patients.Journal of Pharmaceutical and Biomedical Analysis.2023: 115279. 4. Li Z, Pan G, Zhong M, et al.High-Throughput Drug Screen for Potential Combinations With Venetoclax Guides the Treatment of Transformed Follicular Lymphoma.International Journal of Toxicology.2023: 10915818231178693. 5. e Silva, Catarina Sofia Mateus Reis, et al. Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells. Toxicology in Vitro. (2021): 105207. 6. Takei H, Coelho‐Silva J L, Leal C T, et al. Suppression of multiple anti‐apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Science. 2022, 113(2): 597. 7. Suarez M, Blyth G T, Mina A A, et al. Inhibitory effects of Tomivosertib in acute myeloid leukemia. Oncotarget. 2021, 12(10): 955. 8. Tang J, Yao C, Liu Y, et al. Arsenic trioxide induces expression of BCL-2 expression via NF-κB and p38 MAPK signaling pathways in BEAS-2B cells during apoptosis. Ecotoxicology and Environmental Safety. 2021, 222: 112531. 9. Tan M, Ren F, Yang X. Anti-HBV therapeutic potential of small molecule 3, 5, 6, 7, 3′, 4′-Hexamethoxyflavone in vitro and in vivo. Virology. 2021 10. Lee J B, Khan D H, Hurren R, et al. Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production. Blood. 2021 Jul 22;138(3):234-245. doi: 10.1182/blood.2020009081.
收起
BI-3812 Paris saponin VII Dehydrocorydaline nitrate 1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one A09-003 Mcl-1 inhibitor 3 ABT-737 Epieriocalyxin A

相关化合物库

该产品包含在如下化合物库中:
抗癌上市药物库 抗癌药物库 抑制剂库 药物功能重定位化合物库 高选择性抑制剂库 抗癌活性化合物库 EMA 上市药物库 抗癌临床化合物库 共价抑制剂库 儿童药物库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Venetoclax 1257044-40-8 Apoptosis Autophagy BCL bioavailable GDC0199 GDC-0199 orally inhibit Inhibitor Bcl-2 Family GDC 0199 ABT 199 维奈妥拉 ABT-199 ABT199 inhibitor

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼